Platelet reactivity in patients with chronic kidney disease undergoing percutaneous coronary intervention

Abstract

This study aimed to evaluate the platelet reactivity in real-world patients with different chronic kidney disease (CKD) stages after percutaneous coronary intervention (PCI), and to examine whether high residual platelet reactivity (HRPR) is associated with higher incidence of adverse cardiovascular events in a 2-year follow up. A total of 10 724 consecutive patients receiving DAPT with aspirin and clopidogrel after PCI throughout 2013 were enrolled. We applied modified thromboelastography (mTEG) in 6745 patients. Kaplan–Meier analysis and Cox proportional regression analysis were applied to illustrate end points for patients. The prevalence of HRPR for adenosine diphosphate (ADP) was higher in patients with CKD3-5 than patients with CKD1-2 (47.0% vs. 37.3%, p = 0.002), but not for arachidonic acid (AA). No significant difference was observed for MACCE between patients with or without HRPR for ADP (HR 1.004, 95%CI: 0.864–1.167, p = 0.954). Patients with HRPR for ADP was associated with less bleeding events than patients without HRPR for ADP (HR 0.795, 95%CI: 0.643–0.982, p = 0.034). In this large cohort of real-world patients after PCI, the deterioration of renal function was linked to HRPR for ADP. HRPR was not associated with MACCE in patients with CKD in a 2-year follow up. Bleeding risks were significantly lower in PCI patients with versus without HRPR for ADP.

Keywords:

• Chronic kidney disease
• dual antiplatelet therapy
• percutaneous coronary intervention
• platelet reactivity

Acknowledgments

The authors thank staff in the Department of Cardiology and Catheterization Laboratory, Fu Wai Hospital for their research contributions.

Conflict of interest

The authors have no conflicts of interest to declare.

Additional information

Funding

This study was funded by The National Key Research and Development Program of China (No. 2016YFC1301300 & No. 2016YFC1301301); National Natural Science Foundation of China [81470486]; National Key Research and Development Program of China [2016YFC1301301].